Genesis Healthcare, Inc. (NYSE:GEN) COO Paul David Bach sold 6,100 shares of Genesis Healthcare stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $1.73, for a total value of $10,553.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Genesis Healthcare, Inc. (NYSE GEN) traded down 1.66% on Thursday, reaching $1.78. The company’s stock had a trading volume of 146,052 shares. The stock has a 50-day moving average of $2.11 and a 200-day moving average of $3.14. The stock’s market cap is $165.06 million. Genesis Healthcare, Inc. has a one year low of $1.38 and a one year high of $4.75.

Genesis Healthcare (NYSE:GEN) last released its earnings results on Tuesday, May 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.25. Genesis Healthcare had a negative return on equity of 0.81% and a negative net margin of 1.27%. The business had revenue of $1.39 billion for the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the prior year, the business posted ($0.48) EPS. On average, analysts predict that Genesis Healthcare, Inc. will post ($1.22) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Genesis Healthcare (NYSE:GEN)

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Genesis Healthcare, Inc. (GEN) COO Sells 6,100 Shares of Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/06/15/insider-selling-genesis-healthcare-inc-gen-coo-sells-6100-shares-of-stock.html.

Separately, ValuEngine raised Genesis Healthcare from a “strong sell” rating to a “sell” rating in a report on Thursday, June 8th.

A number of institutional investors have recently added to or reduced their stakes in GEN. Columbia Pacific Advisors LLC boosted its position in Genesis Healthcare by 38.6% in the first quarter. Columbia Pacific Advisors LLC now owns 5,294,819 shares of the company’s stock valued at $13,978,000 after buying an additional 1,475,508 shares in the last quarter. First Washington CORP boosted its position in Genesis Healthcare by 15.9% in the first quarter. First Washington CORP now owns 1,457,820 shares of the company’s stock valued at $3,849,000 after buying an additional 199,900 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Genesis Healthcare by 500.3% in the first quarter. JPMorgan Chase & Co. now owns 1,026,169 shares of the company’s stock valued at $2,709,000 after buying an additional 855,240 shares in the last quarter. Vanguard Group Inc. boosted its position in Genesis Healthcare by 0.3% in the first quarter. Vanguard Group Inc. now owns 900,567 shares of the company’s stock valued at $2,378,000 after buying an additional 2,874 shares in the last quarter. Finally, State Street Corp boosted its position in Genesis Healthcare by 15.7% in the fourth quarter. State Street Corp now owns 734,589 shares of the company’s stock valued at $3,124,000 after buying an additional 99,474 shares in the last quarter. Institutional investors and hedge funds own 14.40% of the company’s stock.

About Genesis Healthcare

Genesis Healthcare, Inc is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services.

Receive News & Ratings for Genesis Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genesis Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.